Tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs. According to the World Health Organisation, around 10.8 million people suffered from tuberculosis in 2023, including 6 million men, 3.6 million women, and 1.3 million children. Tuberculosis is curable and preventable. However, multidrug-resistant tuberculosis poses a significant health challenge, with only 2 in 5 drug-resistant tuberculosis patients able to access treatments in 2023. Thus, the emergence of multidrug-resistant tuberculosis strains is accelerating the development of new drugs that are effective against resistant forms.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to tuberculosis.
Treatment for tuberculosis includes a combination of antibiotics, with the treatment duration typically lasting for four, six, or nine months. Isoniazid, rifampin, moxifloxacin, pyrazinamide, ethambutol, and rifapentine are some of the popular antibiotics that are prescribed to patients. Advancements in biotechnology and pharmacology such as high-throughput screening and computational modeling are expected to expedite the development of new drugs. Moreover, the rising investment in tuberculosis research and treatment programs are anticipated to fuel the drug pipeline expansion in the coming years.
This product will be delivered within 3-5 business days.
Report Coverage
The Tuberculosis Drug Pipeline Insight Report by the publisher gives comprehensive insights into tuberculosis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for tuberculosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The tuberculosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from tuberculosis.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to tuberculosis.
Tuberculosis Drug Pipeline Outlook
Tuberculosis (TB) is a multisystemic disease that usually attacks the lungs but can spread to other parts of the body. It is estimated that a quarter of the global population has been infected with the tuberculosis bacteria. Studies show that nearly 5 to 10% of individuals infected with tuberculosis tend to develop symptoms and TB disease. Certain factors such as a weakened immune system, tobacco use, and diabetes, among others, can increase a person’s risk for tuberculosis.Treatment for tuberculosis includes a combination of antibiotics, with the treatment duration typically lasting for four, six, or nine months. Isoniazid, rifampin, moxifloxacin, pyrazinamide, ethambutol, and rifapentine are some of the popular antibiotics that are prescribed to patients. Advancements in biotechnology and pharmacology such as high-throughput screening and computational modeling are expected to expedite the development of new drugs. Moreover, the rising investment in tuberculosis research and treatment programs are anticipated to fuel the drug pipeline expansion in the coming years.
Tuberculosis - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of tuberculosis drugs based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Monoclonal Antibody
- Small Molecule
- Peptide
By Route of Administration
- Oral
- Parenteral
- Others
Tuberculosis - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for tuberculosis. Currently, there are around 55 drugs undergoing Phase II clinical development.Tuberculosis - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the tuberculosis pipeline analysis include monoclonal antibody, small molecule, and peptide. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for tuberculosis.Tuberculosis Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the tuberculosis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in tuberculosis clinical trials:- GlaxoSmithKline
- Serum Institute of India Pvt. Ltd.
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- BioNTech SE
- Archivel Farma S.L.
- Janssen Research & Development, LLC
- Shanghai Jiatan Pharmatech Co., Ltd.
Tuberculosis - Emerging Drugs Profile
Major drugs currently in the drug pipeline are as follows:
Drug: Sudapyridine, Drug: Bedaquiline
Sponsored by Shanghai Jiatan Pharmatech Co., Ltd, the objective of this Phase III, multicenter, double-blind, active-controlled Phase III study is to examine the efficacy and safety of the drug candidate Sudapyridine (WX-081) in combination with a background regimen for the treatment of rifampicin-resistant pulmonary tuberculosis. The study is expected to be completed by October 2026 and has around 450 participants.Biological: VPM1002, Biological: BCG SII
Serum Institute of India Pvt. Ltd. is conducting a Phase III clinical trial aimed at investigating the safety and efficacy of VPM1002 compared to BCG SII against tuberculosis infection in infants. The interventional study has enrolled an estimated 6940 subjects and is expected to be completed by December 2025.Reasons To Buy This Report
The Tuberculosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for tuberculosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within tuberculosis pipeline insights.Key Questions Answered in the Tuberculosis - Pipeline Insight Report
- What is the current landscape of tuberculosis pipeline drugs?
- How many companies are developing tuberculosis drugs?
- How many phase III and phase IV drugs are currently present in tuberculosis pipeline drugs?
- Which companies/institutions are leading the tuberculosis drug development?
- What is the efficacy and safety profile of tuberculosis pipeline drugs?
- What are the opportunities and challenges present in the tuberculosis drug pipeline landscape?
- Which company is conducting major trials for tuberculosis drugs?
- What geographies are covered for tuberculosis clinical trials?
- What are emerging trends in tuberculosis clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Tuberculosis
4 Patient Profile: Tuberculosis
5 Tuberculosis: Epidemiology Snapshot
6 Tuberculosis: Market Dynamics
7 Tuberculosis: Key Facts Covered
8 Tuberculosis, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Tuberculosis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Tuberculosis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Tuberculosis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Tuberculosis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Tuberculosis, Key Drug Pipeline Companies
